This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.35% per year. These returns cover a period from January 1, 1988 through December 2, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pre-Markets Flat Again Ahead of Fed Report Tomorrow
by Mark Vickery
Market participants not look hungry to act until it understands more about the Fed's thinking.
Compared to Estimates, Merck (MRK) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Merck (MRK) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Merck (MRK) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 5.56% and 1.35%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Market Awaits JOLTS Numbers Due Tuesday
by Zacks Equity Research
Market Awaits JOLTS Numbers Due Tuesday.
Big Numbers Ahead: Q2 Earnings, Fed Meeting, Jobs Week
by Mark Vickery
Jobs Week, Fed Week and the busiest week of Q2 earnings so far await us.
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
by Kinjel Shah
AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results. Merck (MRK) and Pfizer's (PFE) phase III studies achieve primary goals.
Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
Investors will likely focus on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.
Countdown to Merck (MRK) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View
by Zacks Equity Research
AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of strong demand for its marketed products.
AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 3.11% and 2.96%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $125.92 in the latest trading session, marking a +1.24% move from the prior day.
What Lies in Store for Healthcare ETFs in Q2 Earnings?
by Sweta Killa
The healthcare sector has gained momentum lately on market rotation, with investors rushing to buy beaten-down stocks while shunning the hot technology sector.
Should You Buy, Sell or Hold Merck (MRK) Ahead of Q2 Earnings?
by Kinjel Shah
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports second-quarter 2024 earnings.
Merck (MRK) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck (MRK) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Merck (MRK) closed at $125.69 in the latest trading session, marking a -0.06% move from the prior day.
Elanco (ELAN) Stock Declines After Sale of Aqua Business
by Zacks Equity Research
Elanco (ELAN) completes the sale of Aqua Business to Merck Animal Health for $1.3 billion to strengthen its financial flexibility and accelerate debt reduction.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Zacks Industry Outlook Eli Lilly, Novo Nordisk, Merck and Pfizer
by Zacks Equity Research
Eli Lilly, Novo Nordisk, Merck and Pfizer have been highlighted in this Industry Outlook article.
Merck (MRK) Up 17% YTD on Keytruda Strength: Should You Buy?
by Kinjel Shah
Merck (MRK) stock is being driven by the strong sales of key products like Keytruda and Gardasil and positive pipeline and regulatory developments.
Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?
by Sundeep Ganoria
Shares of Moderna (MRNA) continue to soar thanks to the encouraging development of its non-COVID pipeline. The company's potential product launches over the next few years make it worth looking at.
Is MannKind (MNKD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how MannKind (MNKD) and Merck (MRK) have performed compared to their sector so far this year.
4 Large Drug Stocks to Watch as Innovation, M&A Pick Up
by Kinjel Shah
Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Pfizer (PFE) are worth retaining in one's portfolio.
Merck (MRK) Stock Moves 0.28%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Merck (MRK) stood at $128.12, denoting a +0.28% change from the preceding trading day.